Abstract
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% confidence interval [CI]: 75.8%-100%]. All patients tolerated treatment well without interruption, death, or serious adverse events.
Keywords:
direct acting antiviral agent; heart transplantation; hepatitis C virus.
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Benzimidazoles / adverse effects
-
Benzimidazoles / therapeutic use*
-
Carbamates
-
Drug Therapy, Combination / adverse effects
-
Drug Therapy, Combination / methods
-
Drug-Related Side Effects and Adverse Reactions / epidemiology
-
Drug-Related Side Effects and Adverse Reactions / pathology
-
Female
-
Fluorenes / adverse effects
-
Fluorenes / therapeutic use*
-
Heart Transplantation*
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Imidazoles / adverse effects
-
Imidazoles / therapeutic use*
-
Male
-
Middle Aged
-
Prospective Studies
-
Pyrrolidines
-
Sofosbuvir / adverse effects
-
Sofosbuvir / therapeutic use*
-
Sustained Virologic Response
-
Transplant Recipients*
-
Treatment Outcome
-
Valine / analogs & derivatives
-
Young Adult
Substances
-
Antiviral Agents
-
Benzimidazoles
-
Carbamates
-
Fluorenes
-
Imidazoles
-
Pyrrolidines
-
ledipasvir
-
Valine
-
daclatasvir
-
Sofosbuvir